Quick Answer
Verrica Pharmaceuticals Inc. reported Research And Development Expense of $8.86 million for the year ending 2025.
- Verrica Pharmaceuticals Inc. showed a decrease of -25.2% in Research And Development Expense from 2024 to 2025.
- This data is from Verrica Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $515.0 thousand | Q2 2017: $977.0 thousand | Q3 2017: $1.12 million | Q4 2017: $1.12 million | Q1 2018: $927.0 thousand | Q2 2018: $3.52 million | Q3 2018: $3.47 million | Q4 2018: $4.92 million | Q1 2019: $4.49 million | Q2 2019: $3.93 million | Q3 2019: $3.05 million | Q4 2019: $3.97 million | Q1 2020: $4.89 million | Q2 2020: $3.52 million | Q3 2020: $4.99 million | Q1 2021: $5.36 million | Q2 2021: $3.45 million | Q3 2021: $3.76 million | Q1 2022: $2.45 million | Q2 2022: $3.94 million | Q3 2022: $2.78 million | Q1 2023: $2.74 million | Q2 2023: $5.73 million | Q3 2023: $6.51 million | Q1 2024: $4.95 million | Q2 2024: $3.32 million | Q3 2024: $2.41 million | Q1 2025: $2.28 million | Q2 2025: $1.85 million | Q3 2025: $2.21 million.
- Over the full 10 years of available data (2017 to 2025), Verrica Pharmaceuticals Inc.'s Research And Development Expense has grown by 137.4%.
- Historical annual values: Fiscal year 2025: $8.86 million | Fiscal year 2024: $11.84 million | Fiscal year 2023: $20.30 million | Fiscal year 2023: $4.50 million | Fiscal year 2022: $12.20 million | Fiscal year 2021: $15.93 million | Fiscal year 2020: $15.67 million | Fiscal year 2019: $15.44 million | Fiscal year 2018: $12.83 million | Fiscal year 2017: $3.73 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: